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Leucine-rich repeat containing protein 10 (LRRC10) is a cardiomyocyte-specific member
of the Leucine-rich repeat containing (LRRC) protein superfamily with critical roles in
cardiac function and disease pathogenesis. Recent studies have identified LRRC10
mutations in human idiopathic dilated cardiomyopathy (DCM) and Lrrc10 homozygous
knockout mice develop DCM, strongly linking LRRC10 to the molecular etiology of DCM.
LRRC10 localizes to the dyad region in cardiomyocytes where it can interact with actin
and α-actinin at the Z-disc and associate with T-tubule components. Indeed, this region
is becoming increasingly recognized as a signaling center in cardiomyocytes, not only
for calcium cycling, excitation-contraction coupling, and calcium-sensitive hypertrophic
signaling, but also as a nodal signaling hub where the myocyte can sense and respond
to mechanical stress. Disruption of a wide range of critical structural and signaling
molecules in cardiomyocytes confers susceptibility to cardiomyopathies in addition to
the more classically studied mutations in sarcomeric proteins. However, the molecular
mechanisms underlying DCM remain unclear. Here, we review what is known about the
cardiomyocyte functions of LRRC10, lessons learned about LRRC10 and DCM from
the Lrrc10 knockout mouse model, and discuss ongoing efforts to elucidate molecular
mechanisms whereby mutation or absence of LRRC10 mediates cardiac disease.
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INTRODUCTION
Dilated cardiomyopathy (DCM) and hypertrophic cardiomyopathy (HCM) are the most common
primary myocardial diseases with a prevalence of at least 1 in 2500 and 1 in 500 individuals,
respectively, (McNally et al., 2013, 2015; Kimura, 2016). DCM is characterized by eccentric cardiac
growth resulting in ventricular dilation and reduced cardiac function without an increase in
ventricular wall thickness (Maillet et al., 2013; van Berlo et al., 2013; Bang, 2016; Kimura, 2016). In
contrast, in HCM, the heart undergoes concentric growth that results in ventricular wall thickening
and reduced ventricular inner diameter, ultimately resulting in reduced cardiac output (Maillet
et al., 2013; van Berlo et al., 2013; Bang, 2016). Both HCM and DCM can progress to congestive
heart failure and are associated with an increased risk of sudden death (Maillet et al., 2013; van
Berlo et al., 2013). While a number of mutations of genes encoding sarcomeric proteins are known
to cause HCM, the genetic etiology of DCM is much more heterogeneous, including mutation
of genes encoding proteins of the Z-disc, costamere, cytoskeleton, sarcolemma, sarcomere, and
nuclear lamina (Cheng et al., 2010; McNally et al., 2013, 2015; Bang, 2016). The most prevalent
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DCM causing mutations are truncations of the sarcomeric
protein titin (Herman et al., 2012; Hinson et al., 2015). DCM
can also occur in response to myocardial infarction or ischemic
damage, which accounts for about half of all cases, while the
majority of remaining cases are idiopathic, underscoring the need
to identify more genetic mutations that underlie DCM (McNally
et al., 2013). The genetic determinants and molecular etiology
underlying DCM in a majority of patients remain unclear.
Leucine-rich repeat containing protein 10 (LRRC10) was
identified based on its cardiac-specific expression pattern
(Nakane et al., 2004; Adameyko et al., 2005; Kim et al., 2007b).
LRRC10 is highly conserved (Kim et al., 2007a) and exclusively
expressed in cardiomyocytes (Kim et al., 2007b; Brody et al.,
2013), suggesting critical cardiac functions for LRRC10. Recently,
studies in Lrrc10 knockout mice (Brody et al., 2012, 2016) and
the identification of LRRC10 mutations in human DCM (Qu
et al., 2015) have sparked interest in the underlying molecular
mechanisms that mediate cardiac disease when LRRC10 is absent
or mutated. LRRC10 belongs to the diverse LRRC protein
superfamily, which is comprised of many proteins that have in
common their leucine-rich repeat (LRR) domains that function
as protein interaction motifs (Kobe and Deisenhofer, 1994,
1995; Kobe and Kajava, 2001). LRRs are sequences of 20–30
amino acids rich in leucine and other aliphatic amino acids.
LRRCs contain two or more LRRs aligned in tandem to form a
curved non-globular, solenoid-shaped structure that is ideal for
mediating protein:protein interactions (Kobe and Deisenhofer,
1994, 1995; Bella et al., 2008). LRRC10 is about 32 kDa, and has
no known functional domains except its seven LRRs (Kim et al.,
2007a,b), suggesting that its molecular functions rely on protein
interactions.
LRRC10 is expressed in the developing heart and upregulated
at birth with elevated protein levels maintained in adulthood
(Brody et al., 2013). Cardiomyocyte-specific expression of
LRRC10 is tightly controlled by the cardiac transcription factors
Nkx2-5, GATA4, and serum response factor (SRF) via conserved
regulatory elements near the LRRC10 promoter region (Fan et al.,
2011; Brody et al., 2013). Investigation of Lrrc10 homozygous
knockout (Lrrc10−/−) mice (Manuylov et al., 2008) has led to
recent discoveries linking LRRC10 to the molecular etiology of
DCM (Brody et al., 2012; Qu et al., 2015). Here, we review
recent findings in the Lrrc10−/− mouse and human idiopathic
DCM patients that implicate LRRC10 in the pathogenesis of
DCM, discuss molecular alterations in the Lrrc10−/− heart that
may contribute to cardiomyopathy, and preface ongoing work
investigating the molecular function of LRRC10.
LRRC10 DELETION CAUSES DILATED
CARDIOMYOPATHY IN MICE
Pioneering studies in zebrafish demonstrated that Lrrc10 is
required for normal cardiac function in vertebrates (Kim
et al., 2007a). Knockdown of Lrrc10 in zebrafish causes cardiac
developmental defects, reduced cardiac function, and lethality
(Kim et al., 2007a). To investigate LRRC10 function in the
mammalian heart, Lrrc10−/− mice were generated (Manuylov
et al., 2008). Lrrc10−/− mice exhibit perinatal cardiomyopathy
and progressive DCM in adulthood (Brody et al., 2012).
Lrrc10−/− mice have reduced cardiac function prior to birth
that progresses to eccentric cardiac growth, ventricular dilation,
and further deterioration of cardiac function in adult mice
(Brody et al., 2012; Figure 1). These studies established the
Lrrc10−/− mouse as a novel model of pediatric cardiomyopathy
and implicated LRRC10 as a candidate DCM gene in humans.
Moreover, Lrrc10−/− mice exhibit greatly reduced cardiac
contractility and exacerbated remodeling in response to pressure
overload induced by transverse aortic constriction (Brody
et al., 2016). The accelerated progression of DCM observed in
Lrrc10−/− mice after pressure overload indicates that deletion
of LRRC10 renders the heart sensitive to disease pathogenesis
during hypertensive remodeling, suggesting that human patients
with mutations in the LRRC10 gene may be prone to more
fulminant disease and DCM under conditions of pressure
overload, such as aortic stenosis or elevated blood pressure.
Lrrc10−/− mice exhibit an uncommon form of cardiac
remodeling characterized by direct progression to ventricular
dilation without compensatory concentric hypertrophic growth,
and cardiac functional impairment in the absence of an increase
in myocyte death or cardiac fibrosis (Brody et al., 2012). In
response to pressure overload Lrrc10−/− mice are capable
of mounting an appropriate concentric cardiac hypertrophy
response, which is accompanied by further eccentric cardiac
growth and dilation with dramatically reduced cardiac functional
performance but similar fibrotic remodeling and cardiomyocyte
death compared to controls (Brody et al., 2016). Thus, LRRC10
appears to be required to maintain cardiac contractile function
and its absence causes dilative cardiac remodeling.
Analyses of adult Lrrc10−/− hearts identified transcriptional
and molecular alterations during the progression of DCM.
FIGURE 1 | Molecular and functional alterations in Lrrc10−/− mice.
Lrrc10−/− mice have reduced cardiac contractility prior to birth that is
associated with the upregulation of actin cytoskeletal transcripts and proteins.
Perinatal cardiac dysfunction in Lrrc10−/− mice progresses to DCM in
adulthood and is associated with upregulation of transcripts involved in
oxidative phosphorylation (ox phos) and myofilament contraction and
activation of Akt and PKCε signaling. L41V or L163I mutations in LRRC10
cause DCM in humans.
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Pathway analysis of gene expression profiling in adult Lrrc10−/−
hearts revealed upregulation of genes involved in oxidative
phosphorylation and myofilament contraction as the most
prominent transcriptional alterations, including cytochrome c
oxidase, ATP synthase, and NADH dehydrogenase genes, and
Tnni3, Tnnt1, Tpm1, and Mybpc3 (Brody et al., 2012; Figure 1).
Despite increased transcript levels, myofilament protein
abundance was not increased in Lrrc10−/− hearts (Brody et al.,
2012), likely because the ordered myofilament lattice contains
stoichiometric quantities of sarcomeric proteins (Michele et al.,
1999) and thus cannot accommodate additional myofilament
proteins beyond the normal rate of turnover, even if transcript
levels are elevated. Upregulation of transcripts involved in
oxidative phosphorylation and myofilament contraction in the
Lrrc10−/− heart are likely a compensatory attempt to bolster
cardiac bioenergetics and sarcomeric proteins, respectively, to
cope with diminished contractile function.
Various signaling pathways play important roles in regulating
cardiac function and the progression to cardiomyopathy and
heart failure (McNally et al., 2013; van Berlo et al., 2013).
However, precise roles of specific signaling pathways in the
progression of DCM have not been fully elucidated. Lrrc10−/−
hearts activate protein kinase C ε (PKCε) and Akt signaling
(Brody et al., 2012; Figure 1). PKCε is activated downstream
of GPCR agonist or mechanical stimulation and is thought
to be cardioprotective in large part due to its augmentation
of mitochondrial function (Inagaki et al., 2003; Iwata et al.,
2005; McCarthy et al., 2005; Budas and Mochly-Rosen, 2007).
Activation of PKCε reduces ventricular dilation and hypertrophy
but does not rescue contractile dysfunction in the cTnTR141W
transgenic mousemodel of DCM (Lu et al., 2014), suggesting that
PKCε may partially ameliorate pathological cardiac remodeling
in some forms of DCM. In this regard, activation of PKCε
potentially prevents the progression to congestive heart failure in
Lrrc10−/− mice.
Akt is a serine/threonine kinase that is protective in
the heart predominantly due to its antiapoptotic effects on
myocytes (Miyamoto et al., 2009). Adult Lrrc10−/− hearts
exhibit elevated levels of active Akt phosphorylated at Ser-473
(Brody et al., 2012), which may limit cardiomyocyte apoptosis.
Activation of Akt and upregulation of oxidative phosphorylation
and myofilament contraction genes observed in Lrrc10−/−
hearts have also been reported in human DCM and heart
failure (Haq et al., 2001; Barrans et al., 2002; Grzeskowiak
et al., 2003; Asakura and Kitakaze, 2009; Colak et al., 2009;
Sopko et al., 2011). Therefore, these molecular alterations may
represent compensatory protective pathways associated with the
progression of DCM. However, it remains unknown how these
signaling pathways are upregulated and what the downstream
effects are in the Lrrc10−/− heart. It is plausible that PKCε or Akt
has novel roles regulating downstream signaling pathways that
function in the setting of cardiac dysfunction and remodeling
caused by LRRC10 deletion. Thus, it would be interesting to
determine whether upregulation of these pathways is indeed
cardioprotective in certain forms of DCM, which would aid in
the identification of therapeutic targets for the treatment of heart
failure patients.
To investigate potential pathogenic mechanisms underlying
DCM caused by LRRC10 deficiency, molecular alterations were
identified in embryonic Lrrc10−/− hearts (Brody et al., 2012).
Gene expression profiling of Lrrc10−/− hearts at embryonic
day (E) 15.5, prior to the development of cardiac dysfunction
at E17.5 or eccentric ventricular remodeling that occurs in
adulthood, revealed upregulation of the actin cytoskeleton and
focal adhesion gene pathways to be the most significantly
dysregulated gene networks (Brody et al., 2012; Figure 1).
Embryonic Lrrc10−/− hearts have elevated transcripts for
integrin β, integrin-linked kinase (ILK), and parvin-α, which
are all induced in the heart in response to biomechanical stress
(Babbitt et al., 2002; Zemljic-Harpf et al., 2007; Sopko et al., 2011).
Upregulation of integrin β1, vinculin, and talin was observed at
the protein level in embryonic Lrrc10−/− hearts (Brody et al.,
2012), suggesting alterations in focal adhesion complexes and
a potential mechanosensing role for LRRC10 (See Discussion
section below).
MOLECULAR FUNCTIONS OF LRRC10
LRRC10 was shown to interact with α-actinin and α-sarcomeric
actin at the Z-disc in cardiomyocytes and directly bind all
actin isoforms (Brody et al., 2012). Interaction of LRRC10 with
actin thin filaments appears to be dynamic as this interaction is
reduced in response to pressure overload (Brody et al., 2016).
Thus, LRRC10 may localize to the Z-disc, T-tubule, or other
locations within the cardiomyocyte in a stimulus-dependent
manner or in response to certain mechanical or molecular
signals, potentially using its interaction with actin at the Z-disc
or cytoskeleton as a docking station.
Transmission electron microscopy analyses demonstrated
that LRRC10 localizes to the dyad region in cardiomyocytes
(Kim et al., 2007b), where the T-tubule comes into close
juxtaposition to the Z-disc and sarcoplasmic reticulum (SR).
The dyad serves as a critical link between the T-tubule network,
SR, Z-disc and cytoskeletal proteins, with roles in regulating
and anchoring ion channels, contractile and structural proteins,
and signaling molecules. Localization of LRRC10 near the Z-
disc positions it at an optimal subcellular location to mediate
signaling responses to mechanical stress (Frank and Frey,
2011). The Z-disc contains mechanical scaffolding and signaling
molecules that structurally and functionally link the myofilament
to the costamere, cytoskeleton, and extracellular matrix (Ervasti,
2003; Luther, 2009; Frank and Frey, 2011). Genetic deletion
or mutation of many genes encoding Z-disc and cytoskeletal
proteins results in DCM in mice and humans, including Cypher
(Vatta et al., 2003; Zheng et al., 2009), muscle LIM protein (MLP)
(Arber et al., 1997; Knoll et al., 2002), integrin-linked kinase
(ILK) (White et al., 2006; Knoll et al., 2007), vinculin (Zemljic-
Harpf et al., 2007), and desmin (Li et al., 1999). Thus, defects
in focal adhesion complex, cytoskeletal, or Z-disc components
can participate in the pathobiology of DCM. MLP anchors
calcineurin at the Z-disc to mediate activation of downstream
NFAT-dependent prohypertrophic gene expression in response
to myocardial infarction (Heineke et al., 2005) and also shuttles
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between the Z-disc and nucleus in response to certain stimuli
(Ecarnot-Laubriet et al., 2000; Boateng et al., 2007, 2009).
Therefore, LRRC10 may bind actin to properly localize, displace,
or regulate the function of an interacting factor at the Z-disc or
may dissociate from the Z-disc to other subcellular locations to
perform regulatory functions.
Other LRRCs bind actin, suggesting that actin binding may
be a general mechanism for LRRCs to localize or dock at specific
cellular locations. For example, LRRC67 binds all actin isoforms
(Wang et al., 2010) and the LRR domain of tropomodulin-
1 mediates its binding to sarcomeric actin in cardiomyocytes
(Tsukada et al., 2011). LRRCs have also been previously reported
to have mechanosensing functions. The striated-muscle-specific
protein, LRRC39, localizes to the M-line in cardiomyocytes
and regulates SRF-dependent transcription (Will et al., 2010),
suggesting that LRRCs may serve as local mechanosensors in
cardiomyocytes.
Lrrc10−/− mice exhibit defective cardiac contractility prior
to ventricular remodeling (Brody et al., 2012), and severely
compromised cardiac function in response to pressure overload
(Brody et al., 2016), indicating that LRRC10 is necessary to
maintain cardiac contractile function. Nonetheless, LRRC10 does
not have a role in directly regulating cardiomyocyte contraction
at the level of the myofilament (Brody et al., 2012, 2016).
No alterations in force development or myofilament calcium
sensitivity were detected in skinnedmyocardium from Lrrc10−/−
hearts (Brody et al., 2012). Although single cell contractility
is not altered at baseline in isolated Lrrc10−/− myocytes,
the contractile response to β-adrenergic stimulation is blunted
(Brody et al., 2016). These data indicate that LRRC10 does
not directly regulate myofilament contraction or cross-bridge
cycling. This is consistent with a mechanosensing function for
LRRC10. In the loaded, intact heart where cardiomyocytes must
sense mechanical stress and preload, LRRC10 is required for
cardiomyocyte contractile function. In contrast, in unloaded
isolated myocytes where mechanical strain cannot be sensed
by the myocyte, LRRC10 is dispensable for cardiomyocyte
contractility.
These data are also consistent with a role for LRRC10
in excitation-contraction coupling such that when LRRC10
is absent or mutated, calcium cycling is defective resulting
in aberrant levels of calcium available at the myofilament to
stimulate contraction (Luo and Anderson, 2013). Although the
reduced contractile response of isolated Lrrc10−/− myocytes
to β-adrenergic stimulation (Brody et al., 2016) could be a
consequence of DCM in Lrrc10−/− mice, it could also be
explained by a primary function for LRRC10 in coupling
adrenergic stimulation to myofilament contraction by facilitating
excitation-contraction coupling.
It is intriguing that LRRCs have been shown to regulate ion
channel activity. Activation of the large-conductance, calcium-
and voltage-activated potassium (BK) channel (encoded by the
Slo1 gene) is regulated by LRRC26, which serves as an auxiliary
γ-subunit to regulate BK channel activity (Braun, 2010; Yan and
Aldrich, 2010; Evanson et al., 2014). Moreover, LRRC52 acts as
a testis-specific γ-subunit regulator of the alkalization-activated
Slo3 potassium channel (Yang et al., 2011), indicating not only
that some LRRCs may function as regulators of the Slo family
of potassium channels (Zhang and Yan, 2014), but also that
LRRCs may provide tissue specificity to the regulation of ion
channel activity. Thus, LRRC10 may serve as a cardiomyocyte-
specific auxiliary protein and regulator of ion channel activity
to mediate appropriate excitation-contraction coupling and
resultant contractility in cardiomyocytes.
ASSOCIATION OF LRRC10 MUTATIONS
WITH DILATED CARDIOMYOPATHY IN
HUMANS
Two heterozygous mutations in LRRC10 were identified in
human patients with idiopathic DCM (Qu et al., 2015). These
studies identified p.L41V and p.L163I missense mutations in
LRRC10 in two unrelated families with DCM. Both mutations
were inherited in an autosomal dominant manner and co-
segregated with DCMwith complete penetrance (Qu et al., 2015).
Residues L41 and L163 are highly conserved, suggesting they are
critical for the structure and/or function of the LRRC10 protein.
Thesemutantsmay not localize properly to the Z-disc or T-tubule
in the dyad region. Alternatively, LRRC10 DCM-associated
mutants may lose their ability to physically or functionally
interact with cofactors. The amino acid substitutions in these
LRRC10 mutants (L41V and L163I) are relatively moderate
biochemical alterations and not predicted to drastically alter the
overall three dimensional conformation of the LRRC10 protein.
Thus, it remains unknown if the L41V or L163I mutants function
as a dominant negative or a loss- or gain-of-function mutation.
Further investigation is necessary to determine precisely how
thesemutations alter themolecular structure of LRRC10 and how
this mechanistically perturbs LRRC10 function to cause disease.
Future sequencing for LRRC10 in human idiopathic DCMwill
be very informative on the prevalence of LRRC10 mutations in
DCM and the potential for additional mutations to contribute
to human cardiac disease. Identification of additional pathogenic
mutations in the LRRC10 protein coupled with molecular studies
of recently identified LRRC10 disease-associated mutants will
shed light on how these mutations disrupt LRRC10 function and
cause DCM.
PERSPECTIVES
Much insight has been gained into the role of LRRC10 in
DCM and molecular mechanisms of DCM pathogenesis in
recent years. The identification of two novel mutations in
LRRC10 that are associated with human idiopathic DCM
has opened the door for investigation into the roles of
LRRC10 in human cardiac disease and the underlying molecular
mechanisms that cause DCM in response to mutation or genetic
ablation of LRRC10. The Lrrc10−/− mouse has provided a
valuable animal model to investigate the molecular function
of LRRC10 that can translate to understanding of human
disease. Molecular evidence and investigation of Lrrc10−/− mice
thus far has pointed to roles for LRRC10 in mechanosensing
and/or excitation-contraction coupling. Future studies will
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investigate calcium cycling in Lrrc10−/− cardiomyocytes to
determine if LRRC10 has a fundamental role in regulation
of excitation-contraction coupling. Identification of proteins
that functionally interact with LRRC10 will be crucial to
determine the molecular functions of LRRC10 and mechanistic
basis of DCM. Further sequencing of LRRC10 in human
idiopathic DCM will reveal the prevalence of LRRC10 mutations
in DCM and potentially identify novel mutations associated
with cardiac disease in humans. Generation of knock-in mice
for human DCM associated LRRC10 mutations will provide
valuable models to investigate molecular mechanisms of DCM.
Moreover, generation of cardiomyocytes from patient-derived
induced pluripotent stem cells (iPSCs) or human pluripotent
stem cells (Sharma et al., 2013) containing DCM-linked
LRRC10 mutations will serve as powerful tools to investigate
human cardiomyopathy. These studies will provide models
to test therapeutic strategies to treat DCM and aid in the
discovery of pathogenic mechanisms underlying DCM in human
patients.
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